Horizon Therapeutics Public Limited Co (fka HZNP)

[surf1944]

7:31AM Horizon Pharma announces Sanofi (SNY) compiegne as additional manufacturing site for DUEXIS (HZNP) 2.54 : Co announced that the United States Food and Drug Administration has approved the use of Sanofi's manufacturing site in Compiegne, France to manufacture DUEXIS (ibuprofen/famotidine), a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg). Valeant Pharmaceuticals' manufacturing site in Laval, Quebec, previously owned and operated by Sanofi, serves as the primary commercial manufacturing site for DUEXIS.